Related Experiment Video
Updated: Mar 27, 2026
07:54
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
19.3K
Pay-for-Performance: Disappointing Results or Masked Heterogeneity?
Adam A Markovitz1, Andrew M Ryan1
11 University of Michigan, Ann Arbor, MI, USA.
Medical Care Research and Review : MCRR
|January 9, 2016
Summary
Pay-for-performance (P4P) in healthcare shows disappointing results, with performance varying by patient demographics and organizational factors. Despite heterogeneity, overall effectiveness of P4P remains questionable.
Area of Science:
- Health Services Research
- Healthcare Policy
- Medical Economics
Background:
- Pay-for-performance (P4P) initiatives aim to improve healthcare quality and efficiency through financial incentives.
- Existing research suggests P4P has yielded largely disappointing results in healthcare settings.
Purpose of the Study:
- To investigate heterogeneity in P4P effectiveness by examining variations in hospital and physician performance.
- To assess how patient, catchment area, organizational, and P4P program characteristics influence P4P outcomes.
Main Methods:
- A comprehensive literature review was conducted to synthesize existing research on P4P effectiveness.
- Analysis focused on identifying factors associated with differential performance in P4P programs.
Main Results:
- Organizational factors (size, practice type, teaching status) and physician characteristics (age, gender) significantly modify P4P performance.
- Worse P4P performance is consistently linked to higher proportions of poor and minority patients in physician practices and hospitals.
- Information technology and staffing levels showed mixed results, while financial incentive characteristics (bonus likelihood, size, costs) had inconsistent effects.
Conclusions:
- Heterogeneity exists in P4P effects, influenced by patient demographics and organizational attributes.
- Healthcare organizations do not appear to respond strategically to financial incentives in P4P.
- The observed variations do not fundamentally change the overall assessment of P4P's limited effectiveness.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
15.5K
11:51Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
Published on: March 2, 2011
15.8K
Related Concept Videos
01:52Regression Toward the Mean
7.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
7.3K
01:11Blinding
4.1K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.1K
01:29Bias in Epidemiological Studies
1.6K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.6K
01:27Confounding in Epidemiological Studies
1.0K
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
1.0K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
240
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
240
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K